Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6899

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6899). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier survival curve graph showing the proportion of patients with relapse over time in days from randomization for Duloxetine compared to placebo. The y-axis represents the proportion of patients with relapse, ranging from 0.0 to 1.0, and the x-axis represents time from randomization to relapse up to 200 days. Two lines are plotted: a solid line for Duloxetine and a dashed line for placebo, illustrating the differences in relapse rates over time.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100. Two curves represent placebo and Duloxetine treatment outcomes.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A Kaplan-Meier curve showing the proportion of patients with relapse over time from randomization to relapse (days). Two treatment groups are compared: placebo with a dashed line and duloxetine with a solid line. The graph plots relapse proportion on the vertical axis against days on the horizontal axis, illustrating lower relapse rates over time for the duloxetine group compared to placebo.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, illustrating patient improvement trends at various pain improvement thresholds.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, illustrating the effectiveness of the treatments in reducing pain.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph comparing the percentage of patients improved relative to percent improvement in pain from baseline. It shows three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The graph illustrates patient improvement over a range of pain reduction percentages from >0 to 100.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline. It compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. Data points illustrate a trend of higher patient improvement percentages with duloxetine doses compared to placebo.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph showing the percentage of patients improved on the vertical axis against percent improvement in pain from baseline on the horizontal axis. The graph compares two groups: Duloxetine 60 mg once daily and placebo, with Duloxetine showing higher percentages of patient improvement across various pain improvement percentages.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved in pain from baseline between placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF), ranging from 0 to 100, and the y-axis shows the percentage of patients improved, ranging from 0 to 100. Two lines plot the data: one for placebo with lower improvement percentages and one for Duloxetine with higher percentages across various pain improvement thresholds.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line chart comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The X-axis represents percent improvement in pain, and the Y-axis shows the percentage of patients improved, with two distinct lines illustrating outcomes for placebo and Duloxetine over a range of improvement percentages.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of Duloxetine hydrochloride depicted as a 2D molecular diagram, showing its key ring structures and functional groups, consistent with the generic ingredient Duloxetine.*

FDA Label Image

Label Image (Lbl500906899)

Duloxetine 30 mg delayed-release capsules package label from A-S Medication Solutions. The label includes dosage form, capsule count of 30, storage instructions to store at 77 degrees Fahrenheit, and packaging details such as lot number and NDC 50090-6899. The capsules are described as enteric-coated gelatin capsules containing equivalent to 30 mg duloxetine hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.